Comparative Pharmacology
Head-to-head clinical analysis: PROSTAPHLIN versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROSTAPHLIN versus UNIPEN.
PROSTAPHLIN vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaphlin (oxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1 and PBP3, leading to inhibition of transpeptidation and cell lysis. It is resistant to staphylococcal beta-lactamases.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
250-500 mg IM or IV every 4-6 hours for moderate to severe infections. For oral use: 250-500 mg every 6 hours on empty stomach.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
0.4-0.8 hours in adults with normal renal function; prolonged in renal impairment (up to 4-6 hours in anuria).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Primarily renal (70-80% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic